. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Gynecol Oncol. 2015 Jun 5;138(2):372–377. doi: 10.1016/j.ygyno.2015.05.040

Table 1.

Tumor latency, number, take rate, and ascites formation.

	OVCAR3	OVCAR4	OVCAR5	OVCAR8	CAOV3	COV362	OVSAHO	OVKATE	Kuramochi	SNU119	UWB1.289 BRCA null
Days Until Sacrifice (IP)	64 days	90 days	26 days	44 days	90 days	90 days	90 days	90 days	90 days	90 days	90 days
Days Until Sacrifice (SC)	36 days	90 days	26 days	27 days	100 days	77 days	90 days	90 days	90 days	90 days	90 days
Average # of IP Tumors/mouse	10.7	11.2	161.4	207.4	8.8	0/8	1.4	0/5	0/5	0/8	0/5
Tumor Range (IP)	1 – 20	7 – 13	0 – 409	148 – 248	2 – 21	N/A	0 – 3	N/A	N/A	N/A	N/A
Tumor Take (IP)	6/6	5/5	4/5	5/5	6/6	0/8	4/5	0/5	0/5	0/8	0/5
Tumor Take (SC)	2/3	4/4	5/5	3/3	0/3	7/9	0/5	4/4	0/3	0/5	0/5
Ascites	1/6	0/5	0/5	4/5	0/6	0/8	0/5	0/5	0/5	0/5	0/5
TP53 status (base/mutation)	248²⁰ C→T	130²⁰ G→C	224²¹ insertion/null	126²⁰ in frame deletion	136²⁰ G→A	220²⁰ T→C	342²⁰ G→A	282²⁰ G→A	281²⁰ C→A	151²⁰ G→A	625 Del AG¹⁹
BRCA1	-	-	-	-	-	1336-splice 871-frame shift	-	-	-	-	-
BRCA2	-	-	-	-	-	-	Del¹⁷	-	2318²⁰ C→T	-	-
MYC	-	-	-	-	-	Ampli¹⁷	-	-	Ampli¹⁷	Ampli¹⁷	-
KRAS	-	-	-	121²⁰ G→T	-	-	-	-	Ampli¹⁷	-	-
CCNE1	Ampli¹⁷	-	-	-	-	-	-	-	-	-	-
RB1	-	-	-	-	-	Ampli¹⁷	Ampli¹⁷	-	-	-	-